Iterum Therapeutics Files 8-K
Ticker: ITRM · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1659323
| Field | Detail |
|---|---|
| Company | Iterum Therapeutics PLC (ITRM) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $20,000,000 m, $36.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, regulatory-filing, financials
TL;DR
Iterum Therapeutics filed a routine 8-K on 10/16/25, likely for administrative or exhibit purposes.
AI Summary
On October 16, 2025, Iterum Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt, but it indicates a routine filing.
Why It Matters
This filing indicates Iterum Therapeutics plc is making a regulatory submission to the SEC, which is standard practice for public companies to disclose material information.
Risk Assessment
Risk Level: low — The filing appears to be a routine administrative or exhibit submission without immediate material business updates, thus posing low risk.
Key Players & Entities
- Iterum Therapeutics plc (company) — Registrant
- October 16, 2025 (date) — Date of Report
- Ireland (location) — State of Incorporation
- +353 1 9038354 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Iterum Therapeutics plc?
The filing is categorized under "Other Events" and "Financial Statements and Exhibits," suggesting it's for routine disclosures or to submit required financial documents.
When was this 8-K report filed?
The report was filed on October 16, 2025.
Where is Iterum Therapeutics plc incorporated?
Iterum Therapeutics plc is incorporated in Ireland.
What is the principal executive office address provided for Iterum Therapeutics plc?
The address is 25 North Wall Quay, Dublin 1, Ireland.
Does this filing indicate any new material business developments for Iterum Therapeutics plc?
Based on the provided excerpt, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' and does not explicitly detail new material business developments.
Filing Stats: 1,036 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2025-10-16 17:18:36
Key Financial Figures
- $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
- $20,000,000 m — ional aggregate gross proceeds of up to $20,000,000 million, not to exceed 21,756,057 ordinar
- $36.2 million — te gross sale proceeds of approximately $36.2 million pursuant to the Sales Agreement and a p
Filing Documents
- d933718d8k.htm (8-K) — 30KB
- d933718dex51.htm (EX-5.1) — 29KB
- g933718dsp5.jpg (GRAPHIC) — 5KB
- 0001193125-25-241556.txt ( ) — 178KB
- itrm-20251016.xsd (EX-101.SCH) — 2KB
- itrm-20251016_lab.xml (EX-101.LAB) — 17KB
- itrm-20251016_pre.xml (EX-101.PRE) — 10KB
- d933718d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit Description 5.1 Opinion of A&L Goodbody LLP 23.1 Consent of A&L Goodbody LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ITERUM THERAPEUTICS PLC Date: October 16, 2025 By: /s/ Corey N. Fishman Name: Corey N. Fishman Title: Chief Executive Officer